Sun Pharmaceutical Industries Ltd (Sun Pharma) manufactures and supplies generic (branded and non-branded) pharmaceuticals to treat conditions such as diabetes, central nervous system disorders, central vascular system disorders, and respiratory and infectious diseases. The company markets these drugs in various dosage forms such as tablets/capsules, semi-solids, liquids and suppositories. It has a portfolio of more than 2,000 marketed products. It manufactures more than 616 APIs, which include a number of APIs with regulated market approval such as US and European drug master files (DMFs).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sun Pharma conducts R&D activities in the field of generics, finished dosage forms, biological support and chemistry. The company's expertise ranges from immediate/controlled release products to complex injectables and differentiated delivery systems. It also concentrates on some complex product forms including soft gel caps, inclusion complexes, osmotic delivery systems, liposome targeted drug delivery, meltabs, aerosols, transdermals, complex ophthalmic technologies, and biodegradable depot-based formulations. The company operates six R&D centers two each in the US and India, one in Canada and Israel. In FY2023, the company incurred an R&D expense of INR23,676 million, which as a percentage of the company's revenue stood at 5.4%. In FY2023, the company filed 616 ANDAs, 67 NDAs, 380 DMFs/CEP and filed for 2,346 patents and received approval for 1,665 patents. It has approved patents for 519 ANDAs, 54 NDAs, and 380 DMFs/CEP.